Free Trial
NASDAQ:TYRA

Tyra Biosciences Q3 2023 Earnings Report

Tyra Biosciences logo
$13.84 +0.47 (+3.52%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tyra Biosciences EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Tyra Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tyra Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Tyra Biosciences' Q3 2025 earnings is scheduled for Thursday, November 6, 2025

Tyra Biosciences Earnings Headlines

Tyra Biosciences (NASDAQ:TYRA) Cut to Sell at Wall Street Zen
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
See More Tyra Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email.

About Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA) (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection.

Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.

View Tyra Biosciences Profile

More Earnings Resources from MarketBeat